[GI hemorrhage with fulminant shock induced by jejunal gastrointestinal stromal tumor (GIST) coincident with duodenal neuroendocrine carcinoma (NET) + neurofibromatosis (NF) -- case report and review of the literature]

Z Gastroenterol. 2005 Mar;43(3):281-8. doi: 10.1055/s-2004-813810.
[Article in German]

Abstract

Background: The incidence of neuroendocrine tumors (NET) and of gastrointestinal stromal tumors (GIST) is 0.5 and 1 - 2 in 100,000; the prevalence of neurofibromatosis is 1 in 3000 live births in Western countries.

Case report: A 43-year-old white woman with a six-month history of meleana, paleness, vertigo and fatigue was not referred to any gastrointestinal doctor for diagnostic work-up. Finally, she collapsed and was admitted to hospital because of an acute gastrointestinal bleeding. Endoscopically the source of bleeding could not be localized while blood in the duodenum and proximal jejunum was demonstrable. The source of bleeding could not be identified by endoscopy, CT scan or angiography. The patient developed a fulminant gastrointestinal hemorrhage with hemoglobin levels below 3.5 g %. An emergency laparotomy and pylorus-preventing Whipple operation was performed. Pathological studies showed a GIST with 3.5 cm diameter of the proximal jejunum which was the source of bleeding. Coincidentally a neuroendocrine carcinoma of the duodenum was found.

Conclusion: This case is the first presentation of the coincidence of a neuroendocrine carcinoma of the duodenum with a jejunal bleeding gastrointestinal stromal tumor in neurofibromatosis type1 which led to hemorrhagic shock. In neurofibromatosis -- even if non-symptomatic -- the increased incidence of tumor needs to be considered.

Publication types

  • Case Reports
  • Comparative Study
  • Lecture

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Carcinoma, Neuroendocrine / complications*
  • Carcinoma, Neuroendocrine / pathology
  • Carcinoma, Neuroendocrine / surgery
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Duodenal Neoplasms / complications*
  • Duodenal Neoplasms / diagnostic imaging
  • Duodenal Neoplasms / pathology
  • Duodenal Neoplasms / surgery
  • Duodenum / pathology
  • Female
  • Follow-Up Studies
  • Gastrointestinal Hemorrhage / etiology*
  • Gastrointestinal Stromal Tumors / complications*
  • Gastrointestinal Stromal Tumors / diagnosis
  • Gastrointestinal Stromal Tumors / diagnostic imaging
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / mortality
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / surgery
  • Humans
  • Imatinib Mesylate
  • Immunohistochemistry
  • Jejunal Neoplasms / complications*
  • Jejunal Neoplasms / surgery
  • Neurofibromatosis 1 / complications*
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / therapeutic use
  • Shock, Hemorrhagic / etiology*
  • Time Factors
  • Tomography, Spiral Computed
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate